Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.APHB · Entity 6329 | Chief Operating Officer | May 30, 2017 | June 01, 2017 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Operating Officer | September 08, 2026 | September 10, 2026 |
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | Chief Business Officer | February 11, 2021 | February 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date May 30, 2017 · Filed June 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2027-05-29 | Direct | 87,161 |
Reported balance
After 2017-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-30 · Grant · Acquired 87,161 · Balance 87,161 F1: 1/4th of the shares subject to the option vest on May 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option vest on May 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years.
IOVANCE BIOTHERAPEUTICS, INC.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,050 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 7,813 · Balance 146,050 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 142,074 |
Reported balance
After 2026-09-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-08 · Tax withholding · Disposed 3,976 · Balance 142,074 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 46,878 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 7,813 · Balance 46,878 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.
Oncternal Therapeutics, Inc.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.05 · Expires 2031-02-11 | Direct | 130,000 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 130,000 · Balance 130,000 F1: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2024 Filed Sep 5, 2024 23:53 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 11,891 | $10.85 | $129,017.35 |
DisclosureSEC source: 0001104659-24-097488 · tm2423453-2_4seq1.xml · nonDerivative · entry 4 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,422 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:53 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 23,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097488 · tm2423453-2_4seq1.xml · nonDerivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:53 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,784 | $10.85 | $19,356.40 |
DisclosureSEC source: 0001104659-24-097488 · tm2423453-2_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,875 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:53 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097488 · tm2423453-2_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| July 15, 2024 Filed Jul 18, 2024 00:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-080616 · tm2419709-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,626 Underlying: Common Stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| July 15, 2024 Filed Jul 18, 2024 00:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,428 | $8.68 | $12,395.04 |
DisclosureSEC source: 0001104659-24-080616 · tm2419709-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,143 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| July 15, 2024 Filed Jul 18, 2024 00:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-080616 · tm2419709-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-068772 · tm2416581-2_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,613 Underlying: Common stock · 3,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,784 | $8.37 | $14,932.08 |
DisclosureSEC source: 0001104659-24-068772 · tm2416581-2_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,758 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-068772 · tm2416581-2_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 23:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-048427 · tm2412101-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,439 Underlying: Common stock · 2,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 23:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,427 | $11.89 | $16,967.03 |
DisclosureSEC source: 0001104659-24-048427 · tm2412101-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,026 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 23:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-048427 · tm2412101-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 14,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031575 · tm248073-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,129 Underlying: Common stock · 14,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 7,287 | $16.96 | $123,587.52 |
DisclosureSEC source: 0001104659-24-031575 · tm248073-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,641 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:17 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 14,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031575 · tm248073-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 46,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031107 · tm248017-3_4seq1.xml · derivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,875 Underlying: Common stock · 46,875 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. F3 · derivative.expiration_date: 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 105,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-031107 · tm248017-3_4seq1.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,470 Underlying: Common stock · 105,470 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004864 · tm243610-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,251 Underlying: Common stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,577 | $8.37 | $13,199.49 |
DisclosureSEC source: 0001104659-24-004864 · tm243610-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,867 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:07 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-004864 · tm243610-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 00:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-109941 · tm2328751-2_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,064 Underlying: Common stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in five equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in five equal quarterly installments. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 00:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,395 | $3.57 | $4,980.15 |
DisclosureSEC source: 0001104659-23-109941 · tm2328751-2_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,631 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| October 16, 2023 Filed Oct 19, 2023 00:04 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-109941 · tm2328751-2_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 22:21 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-081713 · tm2321428-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,877 Underlying: Common stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in six equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in six equal quarterly installments. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 22:21 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,395 | $7.76 | $10,825.20 |
DisclosureSEC source: 0001104659-23-081713 · tm2321428-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,213 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 22:21 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-081713 · tm2321428-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:48 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-046842 · tm2313085-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,690 Underlying: Common stock · 2,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in seven equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in seven equal quarterly installments. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:48 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,395 | $5.64 | $7,867.80 |
DisclosureSEC source: 0001104659-23-046842 · tm2313085-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,795 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:48 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-046842 · tm2313085-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: 2,812 of the restricted stock units ("RSUs") issued to the Reporting Person on January 14, 2022 vested and settled on April 14, 2023. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:25 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 84,380 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001104659-23-029098 · tm238642-2_4seq1.xml · derivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,380 Underlying: Common Stock · 84,380 shares Expires 2033-03-02 F3 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:25 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 42,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-029098 · tm238642-2_4seq1.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,190 Underlying: Common Stock · 42,190 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 11,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-005046 · tm233853d2_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,502 Underlying: Common stock · 11,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in eight equal quarterly installments over the next two years. F5 · derivative.expiration_date: The remaining RSUs will vest in eight equal quarterly installments over the next two years. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,671 | $6.43 | $30,034.53 |
DisclosureSEC source: 0001104659-23-005046 · tm233853d2_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,378 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 21:52 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 11,248 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-005046 · tm233853d2_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: One-third of the restricted stock units ("RSUs") issued to the Reporting Person on January 14, 2022, vested on January 14, 2023. The vested RSUs were settled on January 17, 2023. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:45 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 18,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001601 · tm232380d2_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 18,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023. F5 · derivative.expiration_date: As of December 31, 2022, the remaining RSUs have fully vested and were settled on January 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:45 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 10,553 | $6.11 | $64,478.83 |
DisclosureSEC source: 0001104659-23-001601 · tm232380d2_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,801 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:45 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 18,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001601 · tm232380d2_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This is the second and final vesting of the restricted stock units ("RSUs") issued on June 14, 2021. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 18,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071964 · tm2218629-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 Underlying: Common stock · 18,850 shares Expires not disclosed F4 · security: Represents restricted stock units remaining after deducting the vested shares of common stock and common stock withheld for taxes as set forth in Table I above. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on December 31, 2022, the remaining restricted stock units shall vest and be settled on such date. F6 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on December 31, 2022, the remaining restricted stock units shall vest and be settled on such date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 9,346 | $7.73 | $72,244.58 |
DisclosureSEC source: 0001104659-22-071964 · tm2218629-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,504 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:03 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 18,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-071964 · tm2218629-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This is the first vesting of the restricted stock units issued on June 14, 2021. Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 01:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $15.49 | $0.00 |
DisclosureSEC source: 0001104659-22-005597 · tm223806-2_4seq1.xml · derivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2032-01-14 F3 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 20, 2022 01:31 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005597 · tm223806-2_4seq1.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 21:06 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 37,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-082066 · tm2119923-2_4seq1.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,700 Underlying: Common stock · 37,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units vest as follows: (i) one-half of such shares shall vest and be settled on the one-year anniversary of the date of grant; and (ii) the remaining shares shall vest and be settled on December 31, 2022. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units vest as follows: (i) one-half of such shares shall vest and be settled on the one-year anniversary of the date of grant; and (ii) the remaining shares shall vest and be settled on December 31, 2022. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 00:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $34.91 | $0.00 |
DisclosureSEC source: 0001104659-21-037316 · tm219836d2_4.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common stock · 150,000 shares Expires 2031-03-15 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 18:01 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 130,000 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001209191-21-010905 · doc4.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2031-02-11 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 18:46 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 12,690 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001209191-20-020088 · doc4.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,690 Underlying: Common Stock · 12,690 shares Expires 2030-03-17 F1 · derivative.exercise_date: Fully vested on grant date. Read SEC document |
| March 17, 2020 Filed Jul 31, 2020 21:05 UTC Amendment | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 12,690 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001209191-20-044361 · doc4a.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,690 Underlying: Common Stock · 12,690 shares Expires 2030-03-17 F1 · shares: The original Form 4 reported the acquisition of the Stock Options in the "D" column of Column 5. This amendment is being filed to correctly report the acquisition of the Stock Options in the "A" column of Column 5. F2 · derivative.exercise_date: Fully vested on grant date. Read SEC document |
| September 09, 2019 Filed Sep 9, 2019 19:46 UTC | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001209191-19-048979 · doc4.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-09-09 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date. Read SEC document |
| September 09, 2019 Filed Jul 31, 2020 21:05 UTC Amendment | Oncternal Therapeutics, Inc. ONCT · Entity 89585 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001209191-20-044378 · doc4a.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-09-09 F1 · shares: The original Form 4 reported the acquisition of the Stock Options in the "D" column of Column 5. This amendment is being filed to correctly report the acquisition of the Stock Options in the "A" column of Column 5. F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Persons continued employment or service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.